Stamford

Positioning Itself for Rapid Growth, United Dental Corporation Announces New Board and Leadership Team

Retrieved on: 
Thursday, December 1, 2022
Marketing, Growth, Stamford, Portfolio manager, DCP, Professional, Multimedia, DSO, Natural Resources, MBA, BS, National Dental Examining Board of Canada, Royal Bank, Health, Emory University, Metal, UDC, Bryant University, Telecommunication, Mining, DRS, Morgan Stanley, Dentist, DPO, Royal Bank of Scotland, Pressure, Investment, CFA, Management, Risk management, Finance

MIAMI, Dec. 1, 2022 /PRNewswire/ -- United Dental Corporation ("UDC"), the premier Dental Partnership Organization (DPO) in the U.S. dental market, today announced the following leadership changes to help guide the company through its early growth phase.

Key Points: 
  • MIAMI, Dec. 1, 2022 /PRNewswire/ -- United Dental Corporation ("UDC"), the premier Dental Partnership Organization (DPO) in the U.S. dental market, today announced the following leadership changes to help guide the company through its early growth phase.
  • I would be remiss if I did not heartily recognize Erik's specific effort as President during this transition period."
  • Dr. Nitin Doshi said "UDC's leadership changes are the result of a thoughtful succession planning process that started several months ago.
  • We fully endorse Ray's model and the new Board members will provide strategic, financial, and relationship support to position the Company for rapid growth, profitability, and success."

Tremblant Capital Appoints Brian Rabin and Frank Travers, CFA co-Heads of ESG Strategy

Retrieved on: 
Thursday, February 17, 2022
Investment, Journal, Portfolio manager, Social, Mathematical Methods in the Physical Sciences, Charter of the United Nations, Stamford, UN, Partner, Harvard Business School, CFA, Social science, Economics, Risk, Distinction, CFA Institute, Socially responsible investing, Frank Talk, ESG, MBA, Industry, Lithium, Management, Mont-Tremblant, Northwestern University

NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Tremblant Capital ("Tremblant") today announced that it has appointed Brian Rabin and Frank Travers, CFA as co-Heads of ESG Strategy.

Key Points: 
  • NEW YORK, Feb. 17, 2022 /PRNewswire/ -- Tremblant Capital ("Tremblant") today announced that it has appointed Brian Rabin and Frank Travers, CFA as co-Heads of ESG Strategy.
  • "Tremblant has been managing socially responsible accounts since 2011 and dedicated ESG accounts for the last two years.
  • "Brian and Frank's knowledge of trends and developments shaping ESG, coupled with their industry experience will help us to further this goal."
  • Brian Rabin has 26 years of industry experience, including 23 years on the buyside, where he has spent the past 17 years as a Portfolio Manager at Tremblant.

SpringWorks Therapeutics Announces Clinical Collaboration with AbbVie to Evaluate Nirogacestat in Combination with ABBV-383 in Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Friday, December 10, 2021
Private Securities Litigation Reform Act, Patient, Orphan, COVID-19, Fred Hutchinson Cancer Research Center, LinkedIn, Nasdaq, Dana–Farber Cancer Institute, BCMA, ECD, Royal commission, FDA, Monoclonal antibody, Multiple myeloma, Food, Trial of the century, Gamma secretase, Cancer, Industry, Fibromatosis, European Commission, Research, AbbVie, Precision medicine, Safety, Degenerative disease, Plantar fibromatosis, Therapy, CAR, Goal, CD3, Adult, Solution, GLOBE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Vaccine

STAMFORD, Conn., Dec. 10, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the company has entered into a clinical trial collaboration agreement with AbbVie, Inc. to evaluate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in combination with ABBV-383, AbbVie’s investigational CD3 bispecific antibody directed against B-cell maturation agent (BCMA), in patients with relapsed or refractory multiple myeloma.

Key Points: 
  • Gamma secretase inhibition helps prevent the cleavage and shedding of BCMA from the surface of myeloma cells.
  • We look forward to working with AbbVie to study nirogacestat in combination with ABBV-383, said Saqib Islam, Chief Executive Officer of SpringWorks.
  • Together with our industry-leading collaborators, our goal remains to meaningfully improve clinical outcomes for patients with multiple myeloma.
  • AbbVie and SpringWorks will also form a joint steering committee to manage the clinical study, which is expected to commence in the first half of 2022.

Eagle Bulk Shipping Inc. Completes First Sustainable Biofuel Voyage with GoodFuels

Retrieved on: 
Wednesday, December 8, 2021
Eagle, Frisbee, Company, Carbon, GLOBE, Handymax, CO2, Biofuel, RSB, Miner, ISCC, Efficiency, Industry, Transport, R, Terneuzen, Marketing, Nasdaq, Solution, Renewable energy, Airline

STAMFORD, Conn., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Eagle Bulk Shipping Inc. (Nasdaq: EGLE) (Eagle Bulk, Eagle, or the Company), one of the worlds largest owner-operators within the midsize dry bulk segment, today announced that the Company has successfully completed its first sustainable biofuel voyage in cooperation with GoodFuels, a leading biofuels pioneer for the global transport industry.

Key Points: 
  • STAMFORD, Conn., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Eagle Bulk Shipping Inc. (Nasdaq: EGLE) (Eagle Bulk, Eagle, or the Company), one of the worlds largest owner-operators within the midsize dry bulk segment, today announced that the Company has successfully completed its first sustainable biofuel voyage in cooperation with GoodFuels, a leading biofuels pioneer for the global transport industry.
  • The M/V Sydney Eagle (2015-built SDARI-64 Ultramax) was bunkered with GoodFuels advanced marine biofuel during its port call at Terneuzen, the Netherlands.
  • Jonathan Dowsett, Director of Fleet Performance at Eagle Bulk Shipping, said: Eagle continues to actively explore ways to decarbonize its fleet, while maximizing efficiency in line with international targets to reduce carbon intensity and absolute emissions from shipping.
  • AboutEagle Bulk Shipping Inc.
    Eagle Bulk Shipping Inc. (Eagle or the Company) is a US-based fully integrated shipowner-operator providing global transportation solutions to a diverse group of customers including miners, producers, traders, and end users.

The Lovesac Company Reports Third Quarter Fiscal 2022 Financial Results

Retrieved on: 
Wednesday, December 8, 2021

STAMFORD, Conn., Dec. 08, 2021 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”) today announced financial results for the third quarter of fiscal 2022, which ended October 31, 2021.

Key Points: 

Star Group, L.P. to Host Fiscal 2021 Fourth Quarter Webcast and Conference Call December 9, 2021

Retrieved on: 
Monday, December 6, 2021
News, Coronavirus, Sale, Review, SGU, Risk, Technology, Special, Annual report, Company, NYSE, Form, Heat, Health, Strategic management, Weather, SEC, Star, COVID-19, Gasoline, GLOBE, Marketing, Atmosphere, Climate change, Webcast, Person, Risk management

STAMFORD, Conn., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Star Group, L.P. (the Company or Star) (NYSE: SGU), a leading home energy distributor and services provider, today announced that it will release its fiscal 2021 fourth quarter results after the close of trading on December 8, 2021.

Key Points: 
  • STAMFORD, Conn., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Star Group, L.P. (the Company or Star) (NYSE: SGU), a leading home energy distributor and services provider, today announced that it will release its fiscal 2021 fourth quarter results after the close of trading on December 8, 2021.
  • Members of Star's management team will host a webcast and conference call at 11:00 a.m. Eastern Time the following day, December 9, 2021, to review the three and twelve months ended September 30, 2021.
  • The webcast will be accessible on the companys website, at www.stargrouplp.com , and the telephone number for the conference call is 888-346-3470 (or 412-317-5169) for international callers).
  • Including its propane locations, Star serves customers in the more northern and eastern states within the Northeast, Central and Southeast U.S. regions.

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b/2 Trial Evaluating Nirogacestat in Combination with Elranatamab (PF-06863135) in Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Monday, December 6, 2021
Royal commission, Private Securities Litigation Reform Act, ECD, Patient, CAR, Trial of the century, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, Cancer, European Medicines Agency, PRIME, Industry, BCMA, Dana–Farber Cancer Institute, Precision medicine, GSI, Multiple myeloma, Fred Hutchinson Cancer Research Center, B-cell maturation antigen, Plantar fibromatosis, Solution, Monoclonal antibody, COVID-19, Goal, Orphan, Nasdaq, Twitter, Research, GLOBE, CD3, Adult, EMA, European Commission, FDA, Fibromatosis, Therapy, LinkedIn, Degenerative disease, Food, Pharmaceutical industry, Vaccine

The Phase 1b/2 trial, which is one sub-study of Pfizers umbrella MagnetisMM-4 trial ( NCT05090566 ), is an open-label study evaluating the safety, tolerability and preliminary efficacy of elranatamab in combination with nirogacestat in patients with relapsed or refractory multiple myeloma.

Key Points: 
  • The Phase 1b/2 trial, which is one sub-study of Pfizers umbrella MagnetisMM-4 trial ( NCT05090566 ), is an open-label study evaluating the safety, tolerability and preliminary efficacy of elranatamab in combination with nirogacestat in patients with relapsed or refractory multiple myeloma.
  • The trial is being advanced pursuant to a clinical trial collaboration agreement between SpringWorks and Pfizer.
  • Elranatamab is an investigational B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody being investigated in relapsed or refractory multiple myeloma.
  • Elranatamab has been granted Orphan Drug Designations by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of multiple myeloma.

SpringWorks Therapeutics Announces Full Enrollment of Phase 2b ReNeu Trial Evaluating Mirdametinib in Adult and Pediatric Patients with NF1-Associated Plexiform Neurofibromas

Retrieved on: 
Monday, November 29, 2021
Royal commission, Private Securities Litigation Reform Act, Patient, Trial of the century, Safety, Cancer, AE, Industry, Conference, Neoplasm, MEK, MAPK, Precision medicine, LGG, MEK2, Pigment, Solution, Food, Disease, COVID-19, Pain, Goal, NF1, Nasdaq, Twitter, Survival, Research, Neurofibromatosis, GLOBE, Adult, Incidence, Life expectancy, Orphan drug, Fast Track, MRI, United, FDA, European Commission, Therapy, LinkedIn, PN, MEK1, Genetic disorder, Disability, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Degenerative disease, Pharmaceutical industry

SpringWorks expects to provide an update on anticipated ReNeu trial timelines and milestones at an upcoming company-sponsored R&D Day.

Key Points: 
  • SpringWorks expects to provide an update on anticipated ReNeu trial timelines and milestones at an upcoming company-sponsored R&D Day.
  • Plexiform neurofibromas can cause severe disfigurement, pain, and functional impairment, and patients living with these devastating tumors are in need of new treatments.
  • The ReNeu trial is a multi-center, open-label Phase 2b trial evaluating the efficacy, safety, and tolerability of mirdametinib in patients two years of age and older with an inoperable NF1-associated PN causing significant morbidity.
  • Patients receive mirdametinib at a dose of 2 mg/m2 twice daily (maximum dose of 4 mg twice daily) without regard to food.

SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

Retrieved on: 
Tuesday, November 23, 2021
Patient, Fireside, Cancer, Conference, Industry, Precision medicine, Solution, Investor, Fireside chats, Nasdaq, Twitter, GLOBE, Webcast, Therapy, LinkedIn, Degenerative disease, Event, Pharmaceutical industry

STAMFORD, Conn., Nov. 23, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference, taking place virtually on Tuesday, November 30, 2021, at 3:30 pm ET.

Key Points: 
  • STAMFORD, Conn., Nov. 23, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference, taking place virtually on Tuesday, November 30, 2021, at 3:30 pm ET.
  • A video webcast will be available on the Events & Presentations page within the Investors & Media section of the companys website at https://ir.springworkstx.com .
  • A replay of the webcast will be available on SpringWorks website for a limited time following the conference.
  • SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients living with severe rare diseases and cancer.